Cardium Therapeutics Inc. Comm (CRXM) 0.1980 $CRXM
Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
PR Newswire - Tue Jan 27, 8:00AM CST
Taxus Cardium Pharmaceuticals Group (Symbol: CRXM) today announced a presentation at the 2015 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC. The review and clinical update, entitled "Progress in Angiogenic Gene Therapy for Coronary Artery Disease" was presented by the Company's Chief Scientific Officer, Gabor M. Rubanyi, M.D., Ph.D.
Taxus Cardium Elects Three New Board Members Including PRC Strategic Investor Jiayue Zhang, John Wallace, U.S. Equity Trading Services Executive, And Wei-Wei Zhang, International Gene Therapy Pioneer
PR Newswire - Thu Jan 15, 8:00AM CST
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the election of the following three new directors: Mr. Jiayue Zhang, President of Shanxi Taxus Pharmaceuticals Co. Ltd. (Shanxi Taxus) and Shenzhen Frontsea Taxus Industry Capital Management, Mr. John F. Wallace, President of Philadelphia Financial Services LLC and former Chairman of the Philadelphia Stock Exchange, and Wei-Wei Zhang, M.D., Ph.D. an international pioneer in the research and commercialization of gene-based therapeutics, as new members of the Company's Board of Directors.
Taxus Cardium Reports On Third Quarter 2014 Results And Corporate Development Activities
PR Newswire - Thu Nov 20, 8:00AM CST
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) and its advanced regenerative medicine business units today reported results for the third quarter ended September 30, 2014 and corporate development activities.
Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'
PR Newswire - Wed Aug 13, 8:00AM CDT
Cardium Therapeutics, an operating unit of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the publication of a review article in the Journal of Cardiovascular Pharmacology that concludes a gene therapy product promoting the growth of blood vessels is "highly warranted" to treat about 1 million U.S. heart-disease patients and 6 million more worldwide who are either ineligible or poor candidates for traditional angioplasty, stent placement or bypass surgery.
Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx(R) Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention
Business Wire - Tue Jun 24, 8:01AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (OTCQB: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx(R) Ad5FGF-4, Cardium Therapeutics' angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. The presentation at the 2014 BIO International Convention, now underway at the San Diego Convention Center, will be by Christopher Reinhard, Taxus Cardium's Chief Executive Officer and Cardium Therapeutics' co-founder, at 4:30 pm June 24 in the Mission Beach room.
Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx® Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention
PR Newswire - Tue Jun 24, 8:00AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx® Ad5FGF-4, Cardium Therapeutics' angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. The presentation at the 2014 BIO International Convention, now underway at the San Diego Convention Center, will be by Christopher Reinhard, Taxus Cardium's Chief Executive Officer and Cardium Therapeutics' co-founder, at 4:30 pm June 24 in the Mission Beach room.
Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention
PR Newswire - Thu Jun 12, 8:00AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), announced today that Cardium Therapeutics will announce interim results on the Generx® angiogenic gene therapy product candidate international ASPIRE Phase 3 registration study at the 2014 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 23-26 at the San Diego Convention Center in San Diego, California. The presentation will be made by Cardium's chief executive officer Christopher Reinhard on June 24, 2014, and will also be made available through the Company's website on that day.
Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
PR Newswire - Tue Jan 27, 8:00AM CST
Taxus Cardium Pharmaceuticals Group (Symbol: CRXM) today announced a presentation at the 2015 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC. The review and clinical update, entitled "Progress in Angiogenic Gene Therapy for Coronary Artery Disease" was presented by the Company's Chief Scientific Officer, Gabor M. Rubanyi, M.D., Ph.D.
Taxus Cardium Elects Three New Board Members Including PRC Strategic Investor Jiayue Zhang, John Wallace, U.S. Equity Trading Services Executive, And Wei-Wei Zhang, International Gene Therapy Pioneer
PR Newswire - Thu Jan 15, 8:00AM CST
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the election of the following three new directors: Mr. Jiayue Zhang, President of Shanxi Taxus Pharmaceuticals Co. Ltd. (Shanxi Taxus) and Shenzhen Frontsea Taxus Industry Capital Management, Mr. John F. Wallace, President of Philadelphia Financial Services LLC and former Chairman of the Philadelphia Stock Exchange, and Wei-Wei Zhang, M.D., Ph.D. an international pioneer in the research and commercialization of gene-based therapeutics, as new members of the Company's Board of Directors.
Taxus Cardium Reports On Third Quarter 2014 Results And Corporate Development Activities
PR Newswire - Thu Nov 20, 8:00AM CST
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) and its advanced regenerative medicine business units today reported results for the third quarter ended September 30, 2014 and corporate development activities.
Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'
PR Newswire - Wed Aug 13, 8:00AM CDT
Cardium Therapeutics, an operating unit of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the publication of a review article in the Journal of Cardiovascular Pharmacology that concludes a gene therapy product promoting the growth of blood vessels is "highly warranted" to treat about 1 million U.S. heart-disease patients and 6 million more worldwide who are either ineligible or poor candidates for traditional angioplasty, stent placement or bypass surgery.
Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx(R) Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention
Business Wire - Tue Jun 24, 8:01AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (OTCQB: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx(R) Ad5FGF-4, Cardium Therapeutics' angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. The presentation at the 2014 BIO International Convention, now underway at the San Diego Convention Center, will be by Christopher Reinhard, Taxus Cardium's Chief Executive Officer and Cardium Therapeutics' co-founder, at 4:30 pm June 24 in the Mission Beach room.
Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx® Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention
PR Newswire - Tue Jun 24, 8:00AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx® Ad5FGF-4, Cardium Therapeutics' angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. The presentation at the 2014 BIO International Convention, now underway at the San Diego Convention Center, will be by Christopher Reinhard, Taxus Cardium's Chief Executive Officer and Cardium Therapeutics' co-founder, at 4:30 pm June 24 in the Mission Beach room.
Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention
PR Newswire - Thu Jun 12, 8:00AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), announced today that Cardium Therapeutics will announce interim results on the Generx® angiogenic gene therapy product candidate international ASPIRE Phase 3 registration study at the 2014 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 23-26 at the San Diego Convention Center in San Diego, California. The presentation will be made by Cardium's chief executive officer Christopher Reinhard on June 24, 2014, and will also be made available through the Company's website on that day.
